TherapeuticsMD, Inc. has announced its financial results for the second quarter of 2025. The company reported a net income from continuing operations of $545,000, or $0.05 per basic and diluted common share, a turnaround from a net loss of $1.05 million, or $(0.09) per share, in the same period of 2024. License revenue, primarily driven by the Mayne License Agreement, increased significantly to $1.0 million, up from $234,000 in the second quarter of 2024. This growth is primarily due to changes in sales of licensed products. Total operating expenses decreased by 45.5% to $1.647 million, down $1.376 million from the previous year, largely due to the impairment recognized in the second quarter of 2024. As of June 30, 2025, TherapeuticsMD's cash and cash equivalents stood at $6.1 million. The company continues to explore strategic alternatives, including potential mergers, acquisitions, or other business combinations, but has not set a timetable for this exploration process.